We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01335204
Recruitment Status : Terminated
First Posted : April 14, 2011
Last Update Posted : March 21, 2013
Peregrine Pharmaceuticals
Information provided by (Responsible Party):
Michael Lilly, Medical University of South Carolina

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : March 2013
  Study Completion Date : March 2013